Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyphens Pharma InternationalSGX:1J5 -2.70%82 EBITDA Margin % is 9.08% as of Jun. 2026, which is 16% above its 10-year median of 7.85. GuruFocus rates SGX:1J5 with a GF Score™ of 82/100 and a GF Value™ of S$0.31 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 121 Medical Distribution companies, Hyphens Pharma International ranks better than 64.46% on this metric.
Hyphens Pharma International (SGX:1J5) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hyphens Pharma International EBITDA Margin % Related Terms
Hyphens Pharma International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyphens Pharma International EBITDA Margin % Chart
SGX:1J5 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Hyphens Pharma International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyphens Pharma International EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hyphens Pharma International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hyphens Pharma International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyphens Pharma International (SGX:1J5) has a EBITDA Margin % of 9.08% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hyphens Pharma International and its competitors. This is 16% above median its historical median of 7.85. Over the past decade, Hyphens Pharma International's EBITDA Margin % has ranged from 6.42 to 10.63. According to the industry distribution chart, Hyphens Pharma International ranks #43 out of 121 companies in the Medical Distribution industry, placing it in the top 35.5%.
Is Hyphens Pharma International's EBITDA Margin % too high?
Hyphens Pharma International's current EBITDA Margin % of 9.08% is 16% above median its 10-year median of 7.85. Over the past 10 years, this metric has ranged from a low of 6.42 to a high of 10.63. The Medical Distribution industry median EBITDA Margin % is 4.09. Hyphens Pharma International's value of 9.08% is 122% above this industry median. Based on the distribution chart, Hyphens Pharma International ranks #43 out of 121 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hyphens Pharma International ranks #43 out of 121 companies for EBITDA Margin %. This puts Hyphens Pharma International in the upper half of its industry. The industry median EBITDA Margin % is 4.09. Hyphens Pharma International's value of 9.08% is 122% above this benchmark. Historically, Hyphens Pharma International's own EBITDA Margin % has ranged from 6.42 to 10.63 over the past decade. While the company's 10-year median is 7.85 vs. the industry median of 4.09, Hyphens Pharma International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.09, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyphens Pharma International's current EBITDA Margin % of 9.08% is 122% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hyphens Pharma International and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyphens Pharma International's current EBITDA Margin % is 9.08%, which is 16% above median its own 10-year median of 7.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current EBITDA Margin % is 9.08%, which is 16% above median its 10-year median of 7.85 and 122% above the Medical Distribution industry median of 4.09. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current EBITDA Margin % is 9.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?
Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued.
The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31.
GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.
Key valuation signals for SGX:1J5:
EBITDA Margin %: 9.08% (16% above median its 10-year median of 7.85)
GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
Industry Position: 122% above the Medical Distribution median (#43 of 121)
No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score
Get the complete analysis for SGX:1J5
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1J5 has been successfully added to your 
